UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for kidney cancer in the United Kingdom. Explore treatment pathways including immunotherapy, targeted therapy, and surgery.
Kidney cancer affects ~13,000 people per year in the UK, with renal cell carcinoma (RCC) being the most common type. Clear cell RCC accounts for ~75% of cases. Many kidney cancers are found incidentally during imaging for other reasons. Early-stage disease has excellent outcomes with surgery alone, while advanced kidney cancer has been transformed by immunotherapy and targeted therapy.
Early stage: partial or radical nephrectomy (surgery). Advanced/metastatic: first-line treatment now uses immunotherapy combinations - nivolumab + ipilimumab, or pembrolizumab + axitinib, or avelumab + axitinib. Single-agent TKIs (tyrosine kinase inhibitors) like sunitinib or pazopanib are alternatives. Second-line: nivolumab, cabozantinib, lenvatinib + everolimus, or tivozanib (recently approved by NICE).
Active UK kidney cancer trials: next-generation immunotherapy combinations, bispecific antibodies, ADCs (antibody-drug conjugates), CAR-T cell therapy targeting carbonic anhydrase IX, neoadjuvant immunotherapy (before surgery), and active surveillance strategies. The NHS has specialist kidney cancer centres with dedicated surgical and medical oncology teams.
Free AI-powered matching - no signup required
Search renal cell carcinoma Trials →